论文部分内容阅读
目的了解乳腺浸润性导管癌中雌激素调节蛋白(PS2)和谷胱甘肽S-转移酶π(GSTπ)的表达及其对预后和治疗的指导作用。方法用标记的链亲和素生物素(LSAB)免疫组化法对210例乳腺浸润性导管癌患者的石蜡标本进行PS2和GSTπ的检测。结果PS2的表达阳性率为49.5%,GSTπ几的表达阳性率为48.1%。术后5年和10年生存率从高到低依次为PS2表达阳性/GSTπ表达阴性组、PS2表达阳性/GSTπ表达阳性组、PS2表达阴性/GSTπ几表达阴性组和PS2表达阴性/GSTπ表达阳性组。结论PS2表达阳性/GSTπ表达阴性组患者的预后最好,PS2表达阳性/GSTπ表达阳性组和PS2表达阴性/GSTπ表达阳性组患者的预后次之,PS2表达阴性/GSTπ表达阳性组的预后最差。因此,在临床中应根据患者的情况合理应用内分泌治疗和化疗。
Objective To investigate the expression of estrogen regulatory protein (PS2) and glutathione S-transferase π (GSTπ) in breast invasive ductal carcinoma and their prognostic and therapeutic effects. Methods Paraffin specimens from 210 patients with invasive ductal carcinoma of the breast were tested for PS2 and GSTπ using labeled streptavidin biotin (LSAB) immunohistochemistry. Results The positive rate of PS2 expression was 49.5%, and the positive rate of GSTπ expression was 48.1%. The 5-year and 10-year survival rates were PS2 positive / GSTπ negative, PS2 positive / GSTπ positive, PS2 negative / GSTπ negative and PS2 negative / GSTπ positive group. Conclusion The prognosis of PS2 positive / GSTπ negative patients is the best, PS2 positive patients / GSTπ positive patients and PS2 negative patients / GSTπ positive patients, the prognosis is the second, PS2 negative / GSTπ positive patients have the worst prognosis . Therefore, in clinical practice should be based on the rational use of endocrine therapy and chemotherapy.